FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series D or later / Biotech startups that raised Series D or later in North America

Biotech startups that raised Series D or later in North America

Updated 16 Nov 2026

Reset
Biotech startups that raised Series D or later in North America
One-time CSV
  • 245 funded companies, 219 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-d-plus~north-america.csv245 rows × 18 columns
CompanyCityLast roundAmountDate
OpentronsLong Island CitySeries E$40.0M2026-10-29
PathosNew YorkSeries E$237.0M2026-10-23
Circle PharmaSouth San FranciscoSeries E$92.5M2026-09-16
AlzheonFraminghamSeries F$78.8M2026-09-10
SocureIncline VillageSeries E$156.0M2026-08-27
CraifIrvineSeries D$24.4M2026-08-18
Lycia TherapeuticsSouth San FranciscoSeries D$75.0M2026-06-25
Element BiosciencesSan DiegoSeries E$277.0M2026-06-09

8 rows of the CSV in 5 of its 18 columns.

245
Startups
$41.2B
Total raised
25
Funded in the last 12 months
$2.8B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 245
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Opentrons Unicorn Opentrons develops pipetting robots that automate laboratory experiments in the life sciences. Artificial intelligence Long Island City, United States Series E $40.0M 2026-10-29 $300.2M Y Combinator, SOSV, Khosla Ventures +2 251 to 500 2014
Pathos Pathos is a biotechnology company that uses AI to speed up oncology drug development. Artificial intelligence New York, United States Series E $237.0M 2026-10-23 $684.0M New Enterprise Associates, Lightbank, Builders VC +1 11 to 50 2022
Circle Pharma Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. Biotech South San Francisco, United States Series E $92.5M 2026-09-16 $300.0M Mission BioCapital, Pfizer, The Column Group +1 11 to 50 2012
Alzheon Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. Biotech Framingham, United States Series F $78.8M 2026-09-10 $343.3M Ally Bridge Group, National Institute on Aging 11 to 50 2013
Socure Unicorn Socure provides digital identity verification, fraud prevention, and regulatory compliance software. Artificial intelligence Incline Village, United States Series E $156.0M 2026-08-27 $900.4M Accel, Citi Ventures, JP Morgan +1 501 to 1,000 2012
Craif Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. Artificial intelligence Irvine, United States Series D $24.4M 2026-08-18 $68.7M Global Brain Corporation, VentureOut, ANRI +1 51 to 100 2018
Lycia Therapeutics Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. Biotech South San Francisco, United States Series D $75.0M 2026-06-25 $301.6M Franklin Templeton, Alexandria Venture Investments, Invus +1 11 to 50 2019
Element Biosciences Unicorn Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. Biotech San Diego, United States Series E $277.0M 2026-06-09 $678.0M RA Capital Management, Fidelity, Wellington Management +2 251 to 500 2017
Click Therapeutics Click Therapeutics develops and commercializes software-based prescription treatments for unmet healthcare needs. Biotech New York, United States Series D $50.0M 2026-04-09 $1.1B Silicon Valley Bank, Accelmed, HSBC Innovation Banking +1 101 to 250 2012
Numerion Labs Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. Artificial intelligence San Francisco, United States Series D $19.8M 2026-03-19 $241.4M Y Combinator, Khosla Ventures, Creative Destruction Lab +1 11 to 50 2012
Angitia Biopharmaceuticals Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. Biotech Westlake Village, United States Series D $130.0M 2026-02-05 $406.0M Legend Capital, OrbiMed, Oriza Holdings +1 51 to 100 2018
Elucid Elucid applies AI to medical images to support precision medicine for cardiovascular disease. Biotech Boston, United States Series D $36.5M 2025-10-22 $166.2M National Science Foundation, Sand Hill Angels, IAG Capital Partners +1 101 to 250 2013
Avalyn Pharma Avalyn Pharma develops therapies for idiopathic pulmonary fibrosis and other respiratory diseases. Biotech Seattle, United States Series D $100.0M 2025-07-22 $372.5M Eight Roads Ventures, F-Prime, Wellington Management +2 11 to 50 2011
Arthrosi Therapeutics Arthrosi Therapeutics develops pharmaceutical treatments through clinical research and drug development programs. Biotech San Diego, United States Series E $153.0M 2025-06-23 $277.4M Viva BioInnovator, Xiamen Changrong Investment Management, Viva Ventures Biotech Fund 11 to 50 2018
Variantyx Variantyx offers molecular diagnostics and advanced genetic testing services. Biotech Framingham, United States Series D $36.0M 2025-04-01 $136.5M Pitango VC, Bosch Ventures, Kreos Capital +2 101 to 250 2014
Proscia Proscia develops digital pathology software that helps laboratories manage and analyze pathology data. Artificial intelligence Philadelphia, United States Series D $50.0M 2025-03-19 $129.8M Flybridge, Scale Venture Partners, Fusion Fund +2 101 to 250 2014
Insilico Medicine Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. Artificial intelligence Cambridge, United States Series E $123.0M 2025-03-13 $624.3M Qiming Venture Partners, F-Prime, Warburg Pincus +1 101 to 250 2014
GT Medical Technologies GT Medical Technologies makes medical devices that offer new treatment options for brain tumor patients. Biotech Tempe, United States Series D $53.3M 2025-01-16 $162.5M MedTech Innovator, Arizona Tech Investors, Gilde Healthcare +2 51 to 100 2017
Clear Labs Clear Labs is a biotechnology firm that uses a genomics system to simplify diagnostics. Artificial intelligence San Carlos, United States Series D $30.0M 2025-01-13 $156.5M Plug and Play, Alumni Ventures, Khosla Ventures +1 51 to 100 2014
Inari Unicorn Inari is a seed design and biotechnology company developing seeds for a nature-positive food system. Biotech Cambridge, United States Series G $144.0M 2025-01-07 $753.0M EDBI, Alexandria Venture Investments, CPP Investments +2 251 to 500 2016
ONL Therapeutics ONL Therapeutics develops biopharmaceuticals that protect photoreceptors to preserve vision. Biotech Ann Arbor, United States Series D $65.0M 2024-09-13 $147.9M National Institutes of Health, Johnson & Johnson Innovation, Biosciences Research and Commercialization Center (BRCC) 11 to 50 2011
Moximed Moximed develops therapies for patients with knee osteoarthritis. Biotech Hayward, United States Series D $61.0M 2024-08-13 $244.2M New Enterprise Associates, Vertex Ventures, Cormorant Asset Management +1 11 to 50 2006
Truvian Sciences Truvian Sciences develops an automated benchtop system for lab-accurate blood testing. Biotech San Diego, United States Series D $74.0M 2024-07-17 $208.1M General Catalyst, GreatPoint Ventures, Tao Capital Partners +2 101 to 250 2015
TMRW Life Sciences TMRW Life Sciences manages cryospecimens with automated, software-guided platforms. Biotech New York, United States Series D $28.2M 2024-07-12 $181.7M Google Ventures, Casdin Capital, 5AM Ventures 51 to 100 2018
Formation Bio Unicorn Formation Bio is a drug development company that aims to speed treatments to patients by reimagining clinical trials. Artificial intelligence New York, United States Series D $372.0M 2024-06-26 $528.0M Andreessen Horowitz, Sequoia Capital, Thrive Capital +1 101 to 250 2013
BillionToOne Unicorn BillionToOne offers genetic testing that detects disease through precision diagnostics. Biotech Menlo Park, United States Series D $130.0M 2024-06-21 $425.9M Y Combinator, 500 Global, UpHonest Capital +1 501 to 1,000 2016
Nectero Medical Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. Biotech Tempe, United States Series D $96.0M 2024-04-11 $115.5M Alumni Ventures, Norwest, Aphelion Capital +1 11 to 50 2017
Emulate Emulate creates advanced in vitro models to study how diseases, medicines, and chemicals affect human health. Biotech Boston, United States Series F $47.1M 2024-03-20 $271.3M Alumni Ventures, Qiming Venture Partners, National Institutes of Health 51 to 100 2013
Perfect Day Unicorn Perfect Day produces dairy proteins that are nutritionally identical to proteins from cow's milk. Biotech Berkeley, United States Series E $90.0M 2024-01-05 $801.5M SOSV, K5 Global, Temasek +2 101 to 250 2014
Lyndra Therapeutics Lyndra Therapeutics creates oral dosage forms that release drugs over the long term. Biotech Watertown, United States Series E $101.0M 2023-12-21 $284.6M Polaris Partners, Bill & Melinda Gates Foundation, Invus 51 to 100 2015

Table 1. Biotech startups that raised Series D or later in North America: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 245.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Element Biosciences Unicorn Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. Biotech San Diego, United States Series E $277.0M 2026-06-09 $678.0M RA Capital Management, Fidelity, Wellington Management +2 251 to 500 2017
2 Pathos Pathos is a biotechnology company that uses AI to speed up oncology drug development. Artificial intelligence New York, United States Series E $237.0M 2026-10-23 $684.0M New Enterprise Associates, Lightbank, Builders VC +1 11 to 50 2022
3 Socure Unicorn Socure provides digital identity verification, fraud prevention, and regulatory compliance software. Artificial intelligence Incline Village, United States Series E $156.0M 2026-08-27 $900.4M Accel, Citi Ventures, JP Morgan +1 501 to 1,000 2012
4 Angitia Biopharmaceuticals Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. Biotech Westlake Village, United States Series D $130.0M 2026-02-05 $406.0M Legend Capital, OrbiMed, Oriza Holdings +1 51 to 100 2018
5 Circle Pharma Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. Biotech South San Francisco, United States Series E $92.5M 2026-09-16 $300.0M Mission BioCapital, Pfizer, The Column Group +1 11 to 50 2012
6 Alzheon Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. Biotech Framingham, United States Series F $78.8M 2026-09-10 $343.3M Ally Bridge Group, National Institute on Aging 11 to 50 2013
7 Lycia Therapeutics Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. Biotech South San Francisco, United States Series D $75.0M 2026-06-25 $301.6M Franklin Templeton, Alexandria Venture Investments, Invus +1 11 to 50 2019
8 Click Therapeutics Click Therapeutics develops and commercializes software-based prescription treatments for unmet healthcare needs. Biotech New York, United States Series D $50.0M 2026-04-09 $1.1B Silicon Valley Bank, Accelmed, HSBC Innovation Banking +1 101 to 250 2012
9 Opentrons Unicorn Opentrons develops pipetting robots that automate laboratory experiments in the life sciences. Artificial intelligence Long Island City, United States Series E $40.0M 2026-10-29 $300.2M Y Combinator, SOSV, Khosla Ventures +2 251 to 500 2014
10 Craif Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. Artificial intelligence Irvine, United States Series D $24.4M 2026-08-18 $68.7M Global Brain Corporation, VentureOut, ANRI +1 51 to 100 2018

Table 2. Biotech startups that raised Series D or later in North America: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Y Combinator Startup accelerator Mountain View, United States 4 2% 2 Opentrons, Numerion Labs
2 RA Capital Management Startup incubator Boston, United States 4 2% 1 Element Biosciences
3 Alumni Ventures Angel group Manchester, United States 4 2%
4 National Institutes of Health Entrepreneurship program Bethesda, United States 4 2%
5 Khosla Ventures Venture capital firm Menlo Park, United States 3 1% 2 Opentrons, Numerion Labs
6 T. Rowe Price Private equity firm Baltimore, United States 3 1% 2 Socure, Element Biosciences
7 Wellington Management Private equity firm Boston, United States 3 1% 1 Element Biosciences
8 OrbiMed Private equity firm New York, United States 3 1% 1 Angitia Biopharmaceuticals
9 Deerfield Hedge fund New York, United States 3 1%
10 Google Ventures Corporate venture arm San Francisco, United States 3 1%
11 Baillie Gifford Private equity firm Edinburgh, United Kingdom 3 1%
12 Intel Capital Corporate venture arm Santa Clara, United States 3 1%
13 SOSV Venture capital firm Princeton, United States 2 1% 1 Opentrons
14 New Enterprise Associates Venture capital firm Menlo Park, United States 2 1% 1 Pathos
15 MedTech Innovator Startup accelerator Los Angeles, United States 2 1% 1 Craif

Table 3. Biotech startups that raised Series D or later in North America: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 217 89% $34.3B
Software 31 13% $9.0B
Artificial intelligence 19 8% $7.2B
Hardware 11 4% $1.9B
Cybersecurity 4 2% $1.1B
Energy 3 1% $228.7M
Fintech 2 1% $973.0M
Commerce 1 0% $19.4M

Table 4. Biotech startups that raised Series D or later in North America by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series D+ 245 100% $40.0M

Table 5. Biotech startups that raised Series D or later in North America by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
United States 236 96%
Canada 9 4%

Table 6. Biotech startups that raised Series D or later in North America by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
San Diego 18 7%
Cambridge 12 5%
New York 11 4%
South San Francisco 11 4%
Redwood City 9 4%
San Francisco 7 3%
Boston 5 2%
Santa Clara 5 2%
Mountain View 5 2%
Hayward 4 2%
Berkeley 4 2%
Durham 4 2%

Table 7. Biotech startups that raised Series D or later in North America by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
October 2026 3 12% $327.7M
September 2026 4 16% $757.3M
August 2026 5 20% $434.4M
July 2026 1 4% $67.4M
June 2026 2 8% $352.0M
May 2026 2 8% $92.0M
April 2026 3 12% $170.0M
March 2026 1 4% $19.8M
February 2026 2 8% $245.0M
January 2026 2 8% $305.0M

Table 8. Biotech startups that raised Series D or later in North America: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 25 10% $2.8B
2025 22 9% $2.1B
2024 16 7% $1.3B
2023 12 5% $1.1B
2022 10 4% $1.2B
2021 21 9% $1.5B

Table 9. Biotech startups that raised Series D or later in North America by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 3 1%
2015 to 2019 46 19%
2010 to 2014 52 21%
Before 2010 142 58%

Table 10. Biotech startups that raised Series D or later in North America by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 19 8%
11 to 50 84 35%
51 to 100 69 28%
101 to 250 34 14%
251 to 500 17 7%
501 to 1,000 12 5%
1,001 to 5,000 4 2%
5,001 to 10,000 2 1%
10,001 or more 2 1%

Table 11. Biotech startups that raised Series D or later in North America by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in North America whose last round is Series D or later are on the list?
245, in the file dated 16 November 2026. 25 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 245 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series D or later in North America: 245 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in North America

Other sectors that raised Series D or later in North America

Cite: FundingWatcher, 245 biotech companies in North America whose most recent round is Series D or later, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-d-plus/north-america/